Clinical utility of circulating tumor DNA sequencing with a large panel in patients with advanced soft-tissue sarcomas
Cancer Commun (Lond)
.
2023 Sep;43(9):1051-1054.
doi: 10.1002/cac2.12461.
Epub 2023 Jul 5.
Authors
Julie Blanchi
#
1
2
,
Sofiane Taleb
#
3
,
Arnaud Bayle
3
,
Benjamin Verret
4
,
Maud Toulmonde
5
,
Mariella Spalato-Ceruso
1
5
,
Paul Dubos
5
,
Yech'an Laizet
5
,
Melissa Alame
2
,
Emmanuel Khalifa
2
,
Antoine Italiano
1
3
5
6
Affiliations
1
INSERM, Unité 1312, SARCOTARGET team, Bordeaux, France.
2
Department of BioPathology, Institut Bergonié, Bordeaux, France.
3
Drug Developpement Department, Gustave Roussy, Villejuif, France.
4
Department of Medicine, Gustave Roussy, Villejuif, France.
5
Sarcoma Unit, Institut Bergonié, Bordeaux, France.
6
Faculty of Medicine, University of Bordeaux, Bordeaux, France.
#
Contributed equally.
PMID:
37405935
PMCID:
PMC10508143
DOI:
10.1002/cac2.12461
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Circulating Tumor DNA* / genetics
Humans
Sarcoma* / genetics
Soft Tissue Neoplasms* / genetics
Substances
Circulating Tumor DNA